Transient receptor potential cation channel, subfamily V, member 4 and airway sensory afferent activation: Role of adenosine triphosphate - 01/07/16

Abstract |
Background |
Sensory nerves innervating the airways play an important role in regulating various cardiopulmonary functions, maintaining homeostasis under healthy conditions and contributing to pathophysiology in disease states. Hypo-osmotic solutions elicit sensory reflexes, including cough, and are a potent stimulus for airway narrowing in asthmatic patients, but the mechanisms involved are not known. Transient receptor potential cation channel, subfamily V, member 4 (TRPV4) is widely expressed in the respiratory tract, but its role as a peripheral nociceptor has not been explored.
Objective |
We hypothesized that TRPV4 is expressed on airway afferents and is a key osmosensor initiating reflex events in the lung.
Methods |
We used guinea pig primary cells, tissue bioassay, in vivo electrophysiology, and a guinea pig conscious cough model to investigate a role for TRPV4 in mediating sensory nerve activation in vagal afferents and the possible downstream signaling mechanisms. Human vagus nerve was used to confirm key observations in animal tissues.
Results |
Here we show TRPV4-induced activation of guinea pig airway–specific primary nodose ganglion cells. TRPV4 ligands and hypo-osmotic solutions caused depolarization of murine, guinea pig, and human vagus and firing of Aδ-fibers (not C-fibers), which was inhibited by TRPV4 and P2X3 receptor antagonists. Both antagonists blocked TRPV4-induced cough.
Conclusion |
This study identifies the TRPV4-ATP-P2X3 interaction as a key osmosensing pathway involved in airway sensory nerve reflexes. The absence of TRPV4-ATP–mediated effects on C-fibers indicates a distinct neurobiology for this ion channel and implicates TRPV4 as a novel therapeutic target for neuronal hyperresponsiveness in the airways and symptoms, such as cough.
Le texte complet de cet article est disponible en PDF.Key words : Transient receptor potential, sensory nerves, vagus, cough, ion channels, hypotonicity, ATP
Abbreviations used : AUC, [Ca2+]i, COPD, CV, DiI, DMSO, ECS, K50, αβ-MeATP, NCBI, 4α-PDD, Px1, RAR, TRP, TRPV4
Plan
| Supported by S.A.M., M.S.G., E.D. were funded by project grants from the Medical Research Council (MRC, UK; M.S.G.: G0800195; S.A.M. and E.D.: MR/K020293/1). M.A.W., Y.-M.C., and S.J.B. were supported on an MRC studentship, an MRC/Asthma UK Centre studentship, and the National Heart and Lung Institute, respectively. M.A.W. was also funded by the North West Lung Centre Charity. The human vagus experiments in this study were undertaken with the support of the NIHR Respiratory Disease Biomedical Research Unit at the Royal Brompton and Harefield NHS Foundation Trust and Imperial College London and the Imperial Confidence in Concept Fund. |
|
| Disclosure of potential conflict of interest: A. P. Ford is employed by Afferent Pharma. M. Miralpeix and G. Tarrason are employed by Almirall S.A. J. A. Smith has consultant arrangements with Verona Pharma plc, GlaxoSmithKline, Almirall, Reckitt Benckiser, Glenmark, Xention, Patara, Bayer, and Aboca; has received grants from Verona Pharma, the British Lung Foundation, the Medical Research Council Industry Collaboration Agreement research grant with Almirall, MRC AstraZeneca Mechanisms of Disease, GlaxoSmithKline, Xention, Afferent, Medical Research Council Fellowship, Moulton Charitable Trust, and NeRRe; is an inventor on a patent owned by University Hospital of South Manchester for Vitalograph; has received payment for development of educational presentations from GlaxoSmithKline; and has received travel support from GlaxoSmithKline. M. G. Belvisi has received grants from the Medical Research Council, Afferent, the North West Lung Centre Charity, the National Institute for Health Research Respiratory Disease Biomedical Research Unit and the Royal Brompton and Harefield NHS Foundation Trust, and Imperial College London and the Imperial Confidence Concept Fund; is an associate editor for the American Journal of Respiratory and Critical Care Medicine; is an executive editor for Pharmacology and Therapeutics; has consultant arrangements with Ario Pharma, Aboca, Chiesi Pharma, Imperial College Consultants, Patara, Pulmatrix, Sun Pharma, and Skye Pharma; and is Director of IR Pharma, an Imperial College spinout that conducts contract research. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 138 - N° 1
P. 249 - juillet 2016 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
